title: Chlorpromazine equivalent doses for the newer atypical antipsychotics.
abstract: BACKGROUND
  Several clinical and research applications require an estimation of therapeutic dose equivalence across antipsychotic medications. Since the advent of the newer atypical antipsychotics, new dose equivalent estimations have been needed.
  
  
  METHODS
  The reported minimum effective dose was identified for each newer atypical antipsychotic medication and for haloperidol across all available fixed-dose placebo-controlled studies. Reported minimum effective dose equivalence ratios to haloperidol were then converted to chlorpromazine equivalents using the "2 mg of haloperidol equals 100 mg of chlorpromazine" convention.
  
  
  METHODS
  To identify the fixed-dose studies, the following sources were searched until June 2002: MEDLINE, the bibliographies of identified reports, published meta-analyses and reviews, Cochrane reviews, Freedom of Information Act material available from the Food and Drug Administration, and abstracts from several scientific meetings from 1997 to 2002.
  
  
  RESULTS
  Doses equivalent to 100 mg/day of chlorpromazine were 2 mg/day for risperidone, 5 mg/day for olanzapine, 75 mg/day for quetiapine, 60 mg/day for ziprasidone, and 7.5 mg/day for aripiprazole.
  
  
  CONCLUSIONS
  These equivalency estimates may be useful for clinical and research purposes. The source of the dose equivalency estimation is evidence-based and consistent across medication.
authors.affiliation: Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven , CT 06519, USA. scott.woods@yale.edu
authors.forename: Scott W
authors.initials: SW
authors.lastname: Woods
mesh_terms: D014150:Antipsychotic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000068180:Aripiprazole; D001569:Benzodiazepines; D002746:Chlorpromazine / Q000493:pharmacokinetics* / Q000627:therapeutic use; D003987:Dibenzothiazepines / Q000493:pharmacokinetics / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006220:Haloperidol / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D000077152:Olanzapine; D010879:Piperazines / Q000493:pharmacokinetics / Q000627:therapeutic use; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000069348:Quetiapine Fumarate; D015363:Quinolones / Q000493:pharmacokinetics / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D018967:Risperidone / Q000493:pharmacokinetics / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D013810:Therapeutic Equivalency; D013844:Thiazoles / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D015363:Quinolones; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D010890:Pirenzepine; C092292:ziprasidone; D000068180:Aripiprazole; D006220:Haloperidol; D018967:Risperidone; D000077152:Olanzapine; D002746:Chlorpromazine